Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

dc.contributor.authorMonk, B. J.en_US
dc.contributor.authorLammers, P. E.en_US
dc.contributor.authorCartwright, T.en_US
dc.contributor.authorJacobs, I.en_US
dc.contributor.cuauthorMonk, Bradley J.en_US
dc.date.accessioned2017-02-09T21:45:07Z
dc.date.available2017-02-09T21:45:07Z
dc.date.issued2017en_US
dc.date.monthJanuaryen_US
dc.date.year2017en_US
dc.description.issue1en_US
dc.description.pages(11 pages)en_US
dc.description.volume10en_US
dc.identifier.citationMonk, B. J.; Lammers, P. E.; Cartwright, T.; Jacobs, I. (2017). Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey. Pharmaceuticals (Basel), January 2017, 10(1):(11 pages). doi: http://dx.doi.org/10.3390/ph10010019en_US
dc.identifier.issn1424-8247en_US
dc.identifier.pmid28134851en_US
dc.identifier.urihttp://hdl.handle.net/10504/109509
dc.program.unitSchool of Medicineen_US
dc.program.unitObstetrics and Gynecologyen_US
dc.program.unitPhoenix Campus (Medicine)en_US
dc.titleBarriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Surveyen_US
dc.title.workPharmaceuticals (Basel, Switzerland)en_US
dc.typeJournal Articleen_US
dc.url.link1http://doi.org/10.3390/ph10010019en_US
Files